Chengdu Kanghong Pharmaceutical Group Co., Ltd.
康弘药业
002773
Shenzhen Stock Exchange
Company Profile
Building on over three decades of experience, the company is entering a period of high-quality development. This growth is fueled by our strategic planning and continuous innovation, resulting in significant competitive advantages. These advantages are evident in our strong portfolio of marketed products, robust research pipeline, advanced R&D capabilities, substantial production capacity, talented team, expanding international presence, and well-established brand.
Full description
The company's main business is the R&D, production, and sales of pharmaceuticals (including biologics, patent chinese medicines, and chemical drugs) and medical devices (primarily ophthalmic medical devices). The company's R&D system fosters continuous innovation , established key technologies with significate competitive edge: 1. Biopharmaceutical industrialization technology; 2. Synthetic biology industrialization technology; 3. Full-industry-chain standardized quality control technology for patent Chinese medicines; 4. Novel formulation technology for solid oral medications; 5. Green synthesis technology for chemical APIs (Active Pharmaceutical Ingredients). The company's marketed products primarily include :Conbercept Ophthalmic Injection,Lifitegrast,Pranoprofen Eye Drops,Shugan Jieyu Capsules,Songling Xuemaikang Capsules,Keluoxin Capsules,Danshu Capsules,Yiqing Capsules,Venlafaxine Hydrochloride Sustained-Release Tablets,Aripiprazole Orally Disintegrating Tablets,Aripiprazole Oral Solution,Vortioxetine Hydrobromide Tablets,Escitalopram Oxalate Tablets,Escitalopram Oxalate Oral Solution,Mosapride Citrate Tablets,Mosapride Citrate Dispersible Tablets,Pramipexole Hydrochloride Sustained-Release Tablets,Dexzopiclone Tablets,Medical Devices.